Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
Adding daratumumab to standard myeloma therapy doubled rates of deep, sustained remission in transplant-ineligible patients.
The phase III CEPHEUS trial (ClinicalTrials.gov identifier: NCT03652064) of patients with transplant-ineligible (TIE) or transplant-deferred newly diagnosed multiple myeloma (NDMM; N = 395) demonstrated improved overall ... Rates of sustained MRD negativity (10-5) for ≥12 months (47.2% v 28.3%; P = .0010) and ≥24 months (40.3% v 22.8%; P = .0015) were significantly higher with DVRd.
What the study was
- Study design
- Phase III trial
- Population
- patients
- Sample size
- 395
- Category
- Other
- Maturity
- Exploratory
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Why it surfaced
Score 6/10 [PROMISING_PRELIMINARY]: Phase III trial (Journal Article) matched 'Hematologic malignancies'. Components — novelty:1/3, relevance:2/3, design:2/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.